Metacel Pharms

Metacel was a preclinical-stage biotechnology company focused on the discovery and development of novel therapeutics for metabolic diseases, with a primary emphasis on nonalcoholic steatohepatitis (NASH). The company leveraged deep expertise in metabolic pathways to identify and validate targets involved in lipid metabolism, inflammation, and fibrosis. Metacel's research efforts were centered on developing small molecule inhibitors targeting key enzymes and receptors such as Acetyl-CoA carboxylase (ACC) and Farnesoid X receptor (FXR). The company was eventually acquired by Gilead Sciences, which integrated Metacel's promising metabolic programs into its own extensive liver disease pipeline. This acquisition significantly bolstered Gilead's efforts to address the high unmet medical need in NASH and related metabolic disorders.